Mineralys Therapeutics

@mineralystx.com

75 Followers 261 Following

We're a public, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for hypertension. mineralystx.com

Graphic with dark blue background and a sun in the top right corner. Copy reads (from top): High blood pressure is a year-round risk. Extreme heat can add cardiovascular stress. Icon of water drop: Stay hydrated Icon with a sun and a thermometer: Limit prolonged heat exposure Icon of a stethoscope with a heart in the center: Talk to a healthcare professional
Left side of graphic has a dark blue background with the following text: JULY IS BIPOC Mental Health Awareness Month Chronic stress, anxiety, and depression have been associated with a higher incidence of hypertension in BIPOC populations. Know your numbers, talk to your doctor. On the right side is an image of three people of color (two women and one man) sitting at a table smiling
Left side of graphic features a circle with the words “Dysregulated aldosterone” in the center and 4 icons on the perimeter (from the top, clockwise): - Hypertension with sphygmomanometer icon and heart - Cardiovascular disease with heart icon - Kidney disease with kidney icon - Metabolic diseases with icon of a person Copy on the right reads: A new literature review adds to the growing evidence linking dysregulated aldosterone to organ damage, including hypertension, cardiovascular, kidney, and metabolic diseases.
Know Your Numbers White circle below has an icon of a sphygmomanometer with a red heart in the center.
PRESS RELEASE Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
JUNE IS Alzheimer's and Brain Awareness Month Graphic below shows a small circle with an icon of a heart (left) and a larger circle with an icon of a head and brain. A faint blue line connects both circles.
Press Release Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Image of 4 men - two on left are screened in black and white and the two on the right are shown in color. Text reads: 1 in 2 Men in the the U.S. are living with hypertension
PRESS RELEASE Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Know Your Numbers Image on left shows a sphygmomanometer with a heart icon in the center. On the right in the purple text bubble: < 130/80 mmHg Below it reads: The latest hypertension threshold per AHA/ACC guidelines.
PRESS RELEASE Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Top left: 2026 May 17 Controlling Hypertension Together Initiated by the World Hypertension League WHLeague.org Top right: World Hypertension Day Center image of a doctor taking a patient’s blood pressure seated at a table Below image: Know Your Numbers. Protect Your Future. BP screenings and lifestyle education reduce stroke, heart disease and kidney disease risks.
Image depicts a healthcare interaction between two women: The woman on the left is wearing a blue shirt (patient) has a blood pressure cuff on her arm. The woman on the right is wearing a white coat with a stethoscope around her neck (doctor) and is looking at her patient. Copy in white box reads: > Get your checkup. > Know your blood pressure. > Ask what’s behind it. Copy in purple reads: National Women’s Checkup Day | May 11
LEFT: More than 1-in-10 (14%) adults aged 18 or older (37 million people) have CKD Below 10 icons of people - the first colored red, the second partially colored red and the remainder all in grey CENTER: Approximately 21% of adults in the US are living with both hypertension and CKD (superimposed on a map of the US) with a BP gauge icon and kidney icon below RIGHT: CKD was more common in non-Hispanic Black adults (22%) than in non-Hispanic White adults (13%) or Hispanic adults (12%) Pie chart below (clockwise) RED 22% Non-Hispanic Black Adults BLUE 13% Non-Hispanic White Adults GREY 12% Hispanic Adults
Aldosterone is a steroid hormone that regulates blood pressure and blood volume Purple bar: Aldosterone dysregulation is associated with Below from left: - Sphygmomanometer icon: Hypertension (including resistant hypertension) - Heart icon: Heart failure - Kidneys icon: Chronic kidney disease - Brain with spot: Stroke
Graphic of journal cover: Top right: An Official Journal of ASCPT TITLE: CTS Clinical and Translational Science Open Access (on right in Green bubble) Title of article superimposed on journal cover: First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Circle at right side: Top cited article Wiley 2025
Hypertension prevalence by race/ethnicity in the US Image of the U.S. map in purple with 3 circles - from left: 47% White Adults 44% Hispanic Adults 59% Black Adults Text on the right side of the “map” reads: Racial and ethnic populations are disproportionately impacted by hypertension
Image of Burbon Street in New Orleans, LA Top left corner: American College of Cardiology logo with ACC.26 March 28-30, 2026 - New Orleans, LA Bottom left corner: Booth 1150
Graphic illustrating the relationship between CKD and high blood pressure. COPY: Chronic kidney disease and high blood pressure (BP), or hypertension share a bidirectional relationship Top left is a heart/sphygmomanometer with an arrow (counter clockwise) pointing toward a kidney and another arrow pointing from the kidney to the heart.
Hypertension and reduced kiney function are among the risk factors for cardio-renal-metabolic (CRM) syndrome Graphic with the words "Cardio-Renal-Metabolic Syndrome” inside a circle depicting the risk factors (from top - clockwise): Excess weight with icon of overweight person; Reduced kidney function with icon of kidneys; High blood sugar with icon of glucose monitor; High cholesterol with icon of droplet and arrow pointing up; High blood pressure with a heart and icon of sphygmomanometer
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for the Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Graphic with headline: The Heart is central to Cardiometabolic Health Image shows center circle with the world Aldosterone and 6 circles around it including (clockwise): Obese Uncontrolled Hypertension Treatment Resistant Hypertension Chronic Kidney Disease Vascular & Systemic Inflammation HFpEF & HFrEF Obstructive Sleep Apnea
Cardiovascular Professionals Week February 8-15, 2026 Image of a stethoscope and heart.
"Overall, we believe aldosterone synthase inhibition has the potential to be one of the most transformative advances in cardiovascular medicine in decades - and we're just getting started." -Jon Congleton CEO of Mineralys Therapeurics with headshot photograph
The link between obesity, aldosterone and hypertension
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
PRESS RELEASE Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
AHA Scientific Sessions November 8-10 | New Orleans, LA Booth 4216
Best of JAMA & NEJM JAMA: Lorundrostat in Participants with Uncontrolled Hypertension and Treatment-Resistant Hypertension - The Launch-HTN Randomized Clinical Trial PRESENTER: Manish Saxena, MBBS, MSc November 7th | 2:00 PM to 2:20 PM CST Grand Ballroom A, Convention Center
LATE-BREAKING RESEARCH Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CDK, and Albuminuria: Results from Explore-CKD November 7th | 5:06 PM to 5:18 PM CST Grand Ballroom C, Convention Center
"Mineralys' singular focus on aldosterone biology and its nimble, patient-driven culture position it as a company determined not just to participate in this shift, but to lead it" -Jon Congleton CEO of Mineralys Therapeutics
PRESS RELEASE Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Mineralys Therapeutics Completes Enrollment in Phase 2 Explore-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Hypertension is the leading risk factor for stroke and several heart conditions including: * Coronary artery disease • Heart Failure • Atrial Fibrillation (AFib) Uncontrolled hypertension can lead to: • Chronic Kidney Disease (CKD) • Cognitive decline and dementia • Premature death Aldosterone is a steroid hormone that regulates blood pressure and blood volume. • ~30% of people with hypertension have dysregulated or elevated aldosterone. • Hypertension and other cardio-renal-metabolic syndrome (CRMS) diseases are linked to dysregulated aldosterone including heart failure, kidney disease and obstructive sleep apnea.
"Our vision is to lead in targeted therapies for aldosterone-driven cardio-renal-metabolic (CRM) disease. By targeting aldosterone dysregulation, we aim to meet a critical unmet need with a new mechanism in a field that has seen little innovation in over two decades." -Jon Congleton CEO of Mineralys Therapeutics
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Patients with High Unmet Medical Need
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PRESS RELEASE: Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)